Genus Drug Patent Portfolio
Genus owns 1 orange book drug protected by 3 US patents Given below is the list of Genus's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8734847 | Formulation of indomethacin | 23 Apr, 2030 | Active |
| US8992982 | Formulation of indomethacin | 23 Apr, 2030 | Active |
| US9089471 | Formulation of indomethacin | 23 Apr, 2030 | Active |
Latest Legal Activities on Genus's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Genus.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| 7.5 yr surcharge - late pmt w/in 6 mo, Small Entity | 07 Feb, 2023 | US9089471 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 07 Feb, 2023 | US9089471 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 06 Feb, 2023 | US9089471 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 30 Sep, 2022 | US8992982 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 01 Dec, 2021 | US8734847 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Jan, 2019 | US9089471 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 01 Oct, 2018 | US8992982 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 27 Nov, 2017 | US8734847 |
|
Application ready for PDX access by participating foreign offices
Critical
| 31 Aug, 2015 | US9089471 |
|
Application ready for PDX access by participating foreign offices
Critical
| 31 Aug, 2015 | US8992982 |
|
Recordation of Patent Grant Mailed
Critical
| 28 Jul, 2015 | US9089471 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 28 Jul, 2015 | US9089471 |
| Post Issue Communication - Certificate of Correction | 18 Jul, 2015 | US8992982 |
|
Email Notification
Critical
| 09 Jul, 2015 | US9089471 |
|
Issue Notification Mailed
Critical
| 08 Jul, 2015 | US9089471 |
Genus's Family Patents
Genus drugs have patent protection in a total of 21 countries. It's US patent count contributes only to 23.3% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Genus Drug List
Given below is the complete list of Genus's drugs and the patents protecting them.
1. Tivorbex
Tivorbex is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8734847 | Formulation of indomethacin |
23 Apr, 2030
(4 years from now)
| Active |
| US8992982 | Formulation of indomethacin |
23 Apr, 2030
(4 years from now)
| Active |
| US9089471 | Formulation of indomethacin |
23 Apr, 2030
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tivorbex's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List